ContractMarina Biotech, Inc. • August 12th, 2010 • Pharmaceutical preparations
Amendment No. 3, dated as of the 4th day of June, 2010 (“Amendment No. 3”), to a certain Patent Assignment And License Agreement, dated May 21, 2008, as amended and/or supplemented by Amendment No. 1 dated October 9, 2008, Patent Assignment dated November 3, 2008, and Amendment No. 2 dated June 18, 2009 (collectively, the “Agreement”), by and between Ribotask ApS, having its offices at Unsbjergvej 2A, 5220 Odense SØ, Denmark, being a corporation established under the laws of Denmark (“Assignor”), and MDRNA, Inc. (f/k/a Nastech Pharmaceutical Company Inc.), having its offices at 3830 Monte Villa Pkwy, Bothell, WA 98021, being a corporation established under the laws of the State of Delaware, United States of America (“Assignee”).
ContractPatent Assignment and License Agreement • August 12th, 2010 • Marina Biotech, Inc. • Pharmaceutical preparations • New York
This PATENT ASSIGNMENT AND LICENSE AGREEMENT, dated May 21, 2008 (“Effective Date”), is entered into by and between Ribotask ApS, having its offices at Søndre Boulevard 44, 3, 5000 Odense C, Denmark, being a corporation established under the laws of Denmark (“Assignor”), and Nastech Pharmaceutical Company Inc., having its offices at 3830 Monte Villa Parkway, Bothell, WA 98021, being a corporation established under the laws of the State of Delaware, United States of America (“Assignee”).
FIRST AMENDMENT DATED AS OF JANUARY 29, 2009 TO DEVELOPMENT AND LICENSE AGREEMENT BY AND BETWEEN AMYLIN PHARMACEUTICALS, INC. AND MDRNA, INC. (formerly Nastech Pharmaceutical Company Inc.)Development and License Agreement • August 12th, 2010 • Marina Biotech, Inc. • Pharmaceutical preparations • California
This First Amendment to the Development and License Agreement (the “First Amendment”) is entered into as of January 29, 2009 by and between AMYLIN PHARMACEUTICALS, INC., a corporation organized and existing under the laws of the State of Delaware (“Amylin”), and MDRNA, INC., a corporation organized and existing under the laws of the State of Delaware (formerly known as Nastech Pharmaceutical Company Inc.; “MDRNA”), as an amendment to the Development and License Agreement (the “Agreement”) entered into as of June 21, 2006 by and between Amylin and MDRNA. All capitalized terms used herein shall have the meanings given in the Agreement.
ContractMarina Biotech, Inc. • August 12th, 2010 • Pharmaceutical preparations
Amendment No. 2, dated June 18, 2009 (“Amendment No. 2”), to a certain Patent Assignment And License Agreement, dated May 21, 2008, as amended October 9, 2008 (the “Agreement”), by and between Ribotask ApS, having its offices at Promenadebyen 2, 8. sal, lejl. 4, 5000 Odense C, Denmark, being a corporation established under the laws of Denmark (“Assignor”), and MDRNA, Inc. (f/k/a Nastech Pharmaceutical Company Inc.), having its offices at 3830 Monte Villa Pkwy, Bothell, WA 98021, being a corporation established under the laws of the State of Delaware, United States of America (“Assignee”).
ContractMarina Biotech, Inc. • August 12th, 2010 • Pharmaceutical preparations
Amendment No. 1, dated October 9, 2008, to a certain Patent Assignment And License Agreement, dated May 21, 2008 (the “Agreement”), by and between Ribotask ApS, having its offices at Søndre Boulevard 44, 3, 5000 Odense C, Denmark, being a corporation established under the laws of Denmark (“Assignor”), and MDRNA, Inc. (f/k/a Nastech Pharmaceutical Company Inc.), having its offices at 3830 Monte Villa Pkwy, Bothell, WA 98021, being a corporation established under the laws of the State of Delaware, United States of America (“Assignee”).
